Patients with secondary muscle-invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy had worse clinical outcomes than patients treated similarly with primary MIBC. These contrasting clinical outcomes may have resulted from differing rates of cisplatin-sensitizing ERCC2 mutations that were enriched in primary MIBC.
- Bladder cancer
- Muscle-invasive bladder cancer
- Neoadjuvant chemotherapy
- Non–muscle-invasive bladder cancer
- Radical cystectomy
ASJC Scopus subject areas